olaratumab sold brand name lartruvo monoclonal antibody medication developed eli lilly company treatment solid tumors directed plateletderived growth factor receptor removed united states european union markets due insufficient proof medical advantage see medical uses olaratumab used combination doxorubicin treatment adults advanced softtissue sarcoma sts cured cancer surgery radiation therapy previously treated randomised controlled trial sts patients olaratumab plus doxorubicin improved median progressionfree survival months compared doxorubicin alone p narrowly missing statistical significance overall survival months p highly however announce phase trial find advantage adding olaratumab doxorubicin therefore january fda ema decided recommend starting olaratumab soft tissue april european medicines agency explicitly requested marketing authorisation medicine shortly afterwards german physicians medicines commission reported olaratumab removed german market weeks asked doctors treat new patients drug outside clinical lilly subsequently voluntarily withdrew approval united drug contraindications apart hypersensitivity studies serious side effects combination olaratumabdoxorubicin neutropenia low count neutrophil white blood cells severity grade patients musculoskeletal pain grade patients common milder side effects lymphopenia headache diarrhoea nausea vomiting mucositis reactions infusion typical effects cancer therapies pharmacokinetic interactions doxorubicin observed studies monoclonal antibody olaratumab neither metabolised cytochrome liver enzymes transported transmembrane pumps thus expected interact relevantly olaratumab inhibits growth tumour cells blocking subunit alpha plateletderived growth factor receptor type tyrosine intravenous infusion olaratumab volume distribution litres steady state biological halflife olaratumab originally developed imclone systems acquired eli lilly phase clinical trial conducted japanese patients september followed phase ii trial patients starting october february european medicines agency assigned olaratumab orphan drug status treatment softtissue european commission granted conditional marketing authorisation based mentioned phase ii study valid throughout european union november previously considered promising drug fda granted olaratumab fast track designation breakthrough therapy designation priority review status october us fda issued accelerated approval notice use olaratumab doxorubicin treat adults certain types softtissue sarcoma based phase iii trial completed unfortunately showed benefit addition olaratumab noted results led withdrawal approval united states europe httpsenwikipediaorgwikiolaratumab